Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Date publication

février 2018

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain

Tous les auteurs :
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29077785

Résumé

Cisplatin-based combination chemotherapy is the standard treatment of advanced urinary tract cancer (aUTC), but 50% of patients are ineligible for cisplatin according to recently published criteria. We used a multinational database to study patterns of chemotherapy utilization in patients with aUTC and determine their impact on survival.

Mots clés

Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cisplatin, administration & dosage, Humans, Retrospective Studies, Treatment Outcome, Urologic Neoplasms, drug therapy

Référence

Ann. Oncol.. 2018 Feb 1;29(2):361-369